Biologics·Aug 2, 2026
For most U.S. practices, MSC-based therapy means same-day autologous minimally manipulated preparations delivered with careful patient selection and honest positioning. This is the protocol framework that has held up in the current regulatory environment.
Positioning your MSC-based program
- Call the therapy what it is: same-day autologous minimally manipulated cell therapy derived from bone marrow (BMAC) or mechanically-processed adipose.
- Do not market MSC counts or "billions of stem cells" — same-day preparations do not reliably deliver such counts.
- Do not market systemic or anti-aging effects; keep indications focal and evidence-supported.
- For patients asking about culture-expanded MSCs, discuss the international landscape candidly and refer to clinical trials when appropriate.
Patient selection
- Moderate joint degeneration with intact structural anatomy.
- Chronic tendinopathy refractory to PRP.
- Chronic wound with a defined, addressable etiology.
- Poor candidates: end-stage joint disease, active infection, unmanaged systemic inflammatory disease, unrealistic expectations.
Knee osteoarthritis protocol (BMAC/MSC)
- Harvest 40–60 mL iliac crest, concentrate to 4–8 mL BMAC.
- Ultrasound-guided intra-articular delivery.
- Pre-injection ECSWT 48–72 h prior to prime the environment.
- Post-injection HPLT weekly ×4 for cellular energy support.
- Non–weight-bearing 48 h; graded return over 4 weeks; loading program from week 2.
- PRP boost at 6 months for maintenance.
Rotator cuff and shoulder protocols
- Adjunct to arthroscopic repair — BMAC applied at the tendon footprint.
- For partial thickness tears — ultrasound-guided BMAC delivery.
- Rehab per surgical protocol; ECSWT + HPLT off-days.
Osteonecrosis of femoral head (early)
- Core decompression with intraosseous BMAC delivery.
- Non–weight-bearing post-op per surgical directive.
- Best outcomes in Ficat I–II disease.
Non-union fracture
- BMAC + structural graft at operative revision.
- Rigid fixation; standard immobilization.
Chronic wound protocol
- BMAC applied topically to debrided wound bed under an amniotic membrane cover.
- Compression / offloading per etiology.
- Weekly reassessment for 4–8 weeks.
Adjunct sequencing
- ECSWT: mechanotransductive priming pre-delivery.
- HPLT: mitochondrial support post-delivery.
- PRP: 6-month maintenance boost.
- Nutritional and metabolic optimization: vitamin D, glycemic control, smoking cessation dramatically improve outcomes.
Comparing to alternatives
- vs PRP: BMAC delivers cells + growth factors and outperforms PRP in moderate-severe joint disease; PRP wins on cost and simplicity in earlier disease.
- vs surgery: BMAC does not reverse structural damage; it can delay or bridge surgical intervention in appropriately selected patients.
- vs international culture-expanded MSC therapy: higher cell dose available abroad, greater cost and regulatory ambiguity, evidence base still maturing for many advertised indications.
Consent and documentation
- Written consent that reflects same-day autologous minimally manipulated framing.
- Document harvest volume, processing method, delivery route, and post-procedure plan.
- Track outcomes with validated measures — WOMAC, VAS, patient-reported global impression of change.
- Follow up at 6 weeks, 3 months, 6 months, 12 months.
Common failure modes
- Overpromising outcomes based on international trial data that used culture-expanded product.
- Skipping the pre- and post-procedure device pairing that improves biological outcome.
- Applying MSC-based therapy to inappropriate structural pathology.
- Losing the case narrative through poor outcome documentation.